CADL SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Candel Therapeutics
CADL SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Candel Therapeutics |
| [17-November-2026] |
Candel pointed investors to a fourth-quarter 2026 BLA submission for aglatimagene as recently as August 13, 2026. On November 12, that target moved to mid-2027, CADL fell more than 26% the following day, and shareholders who lost money may have rights to recover. NEW YORK, Nov. 17, 2026 /PRNewswire/ -- Candel Therapeutics (NASDAQ: CADL) shareholders saw over 26% of their position's value disappear after the Company announced on November 12, 2026 that its Biologics License Application for aglatimagene would slip from the fourth quarter of 2026 to mid-2027. If you bought CADL and lost money on this announcement, you have rights, and you are encouraged to act now. Shareholders who suffered losses can assess their CADL loss and protect their rights here, or contact Joseph E. Levi, Esq. at jlevi@SueWallSt.com or (888) SueWallSt.
Ninety-one days earlier, the target was Q4 2026. On August 13, 2026, Candel's quarterly results release described its manufacturing campaign as "progressing well" and "a critical CMC activity to enable the anticipated BLA submission in Q4 2026." The November 12 announcement cited "timelines associated with certain assay refinement" and ongoing FDA dialogue, pushing the submission back by roughly half a year. SueWallSt notifies investors of a pending investigation into potential securities law violations connected to Candel's BLA timing statements. Shareholders who still hold CADL and those who sold after the drop may both be eligible. Eligibility depends on when shares were purchased and the losses suffered, not on whether the position is still open. If CADL's November 13 drop cost you money, start your no-cost CADL loss review or call (888) SueWallSt. WHY SUEWALLST: SueWallSt is powered by Levi & Korsinsky LLP. Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured billions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Frequently Asked Questions About the CADL Investigation Q: Which statements are being investigated as potentially misleading?A: The investigation concerns whether Candel Therapeutics made materially false or misleading statements regarding the timing of its aglatimagene Biologics License Application, including statements anticipating a submission in the fourth quarter of 2026. After the Company disclosed on November 12, 2026 that the submission had moved to mid-2027 amid FDA discussions over assay refinement, the stock price declined sharply. Q: When did Candel Therapeutics allegedly mislead investors?A: The investigation concerns statements made before the November 12, 2026 disclosure, including the Company's August 13, 2026 statements anticipating a fourth-quarter 2026 BLA submission, that allegedly caused investors to purchase securities at inflated prices. Q: Who is eligible to participate in the CADL investigation?A: Investors who purchased CADL stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses, not on whether you still hold the shares. Q: What do CADL investors need to do right now?A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible to participate in the investigation. Q: What documents do I need to participate?A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices. Q: What if I already sold my CADL shares -- can I still recover losses?A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought CADL and sold at a loss may still participate in the investigation. Q: Do I need to go to court or give testimony?A: No. Participating in the investigation does not require court appearances or depositions. If legal action is later pursued, the overwhelming majority of affected investors never appear in court either. Q: What does it cost me to participate?A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys' fees and expenses subject to court approval. CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 33 Whitehall Street, 27th Floor New York, NY 10004 Tel: (888) SueWallSt Fax: (212) 363-7171 Attorney Advertising. Prior results do not guarantee similar outcomes.
SOURCE SueWallSt.com | ||
Company Codes: NASDAQ:CADL |












